However, whether blocking CXCL8/CXCR1/2 signal or LAG3/LSECtin can increase the efficacy of anti-PD-1/PD-L1 or anti-CTLA4 in patients with colon cancer is still lack of effective experimental verification. Here, CXCR1 is linked to malignant colon neoplasm.